Detalhe da pesquisa
1.
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Ann Oncol
; 34(10): 899-906, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597579
2.
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Ann Oncol
; 31(11): 1518-1525, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32798689
3.
ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4).
Ann Oncol
; 31(6): 674-696, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199930
4.
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
Pharmacogenomics J
; 17(6): 521-527, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27549341
5.
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Br J Cancer
; 109(9): 2331-9, 2013 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24084768
6.
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Ann Oncol
; 24(8): 2011-6, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23613476
7.
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Breast Cancer Res Treat
; 132(3): 1063-72, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22200869
8.
Modeling hot flushes and quality of life in breast cancer survivors.
Climacteric
; 14(1): 171-80, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20450413
9.
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy.
Br J Cancer
; 102(2): 294-300, 2010 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-19953095
10.
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Br J Cancer
; 103(3): 291-6, 2010 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20606683
11.
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Pharmacogenomics J
; 9(4): 258-64, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19421167
12.
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer.
Ann Oncol
; 19(10): 1669-80, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18522932
13.
Adiposity Results in Metabolic and Inflammation Differences in Premenopausal and Postmenopausal Women Consistent with the Difference in Breast Cancer Risk.
Horm Cancer
; 9(4): 229-239, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29546532
14.
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.
Ann Oncol
; 18(12): 1927-34, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17998286
15.
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Breast
; 27: 99-104, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27058233
16.
Does tamoxifen cause cancer in humans?
J Clin Oncol
; 16(2): 779-92, 1998 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-9469370
17.
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.
J Clin Oncol
; 19(8): 2334-56, 2001 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11304787
18.
New prognostic factors for breast cancer recurrence.
Semin Oncol
; 28(1): 53-67, 2001 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11254867
19.
The Role of c-erbB-2 as a predictive factor in breast cancer.
Breast Cancer
; 8(3): 171-83, 2001.
Artigo
em Inglês
| MEDLINE | ID: mdl-11668238
20.
A SNP in steroid receptor coactivator-1 disrupts a GSK3ß phosphorylation site and is associated with altered tamoxifen response in bone.
Mol Endocrinol
; 26(2): 220-7, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22174377